<DOC>
	<DOCNO>NCT00678210</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety , 12 week , 3 dose regimen CP-690,550 treatment adult moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Effectiveness Safety 3 Dosing Regimens CP-690,550 Placebo Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have diagnose plaque psoriasis least 6 month . Have plaque psoriasis cover least 15 % total body . Be candidate phototherapy systemic treatment psoriasis ( either na√Øve history previous treatment ) . Be willing able comply schedule visit , treatment plan study procedure . Currently nonplaque form psoriasis druginduced psoriasis . Subject discontinue systemic therapy and/or topical therapy treatment psoriasis discontinue phototherapy . Subject participate another trial use investigational agent procedure . Women pregnant breastfeeding consider become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>dose response ; PASI 75 response endpoint ; subject moderate severe chronic plaque psoriasis</keyword>
</DOC>